Here we studied the expression level of ICAM-1 in 102 diffuse large B-cell lymphoma patients and investigated its association with rituximab treated progression-free survival (PFS) and overall survival (OS). This evidence concerns the gene ICAM1 and diffuse large B-cell lymphoma.